Taken together, our data suggest that NPM1 is required for WNT-driven intestinal cell proliferation and tumor initiation; this dependency persists after oncogenic KRAS activation, which drives resistance to epidermal growth factor receptor and mTOR inhibition. Here, KRAS is linked to neoplasm.